Tilda

Tilda's Clinical Trial Network

Tilda operates a high-performance clinical trial site network, highly regarded for its technology-led approach. The network is a critical resource for sponsors and Contract Research Organizations (CROs) due to its efficiency in conducting phases 2 to 4 of clinical trials. With over 250 completed studies and more than 2,500 patients, Tilda's network spans four locations, specializing in nine therapeutic areas. This extensive experience ensures that trials are run with precision, and patient care is prioritized.

Tilda's Technological Innovations

Tilda leverages best-in-class workflow automation software to streamline clinical trials. This technological edge enables Tilda to achieve remarkable milestones, such as reducing query days-outstanding by 80% and generating 50% fewer queries during studies. Their real-time tracing and automation technologies have resolved 75% of queries quickly, with an average query close-out time of just three days compared to the study-wide average of 25 days. Such innovations allow Tilda to execute trials at twice the speed of traditional methods while maintaining high data integrity and patient care standards.

Tilda's Performance in Alzheimer’s Studies

Tilda has achieved significant rankings in Alzheimer’s studies, highlighting its expertise and efficiency. The company ranked in the top 5% for the number of screens per week and 19th overall for total screens out of 226 sites. This high performance underscores Tilda's ability to handle complex clinical trials effectively. By focusing on phases 2 to 4, Tilda ensures that crucial late-stage development receives the attention and resources necessary for successful outcomes.

Tilda's Achievements in Infectious Disease Studies

Tilda has made notable strides in infectious disease studies, achieving a #1 top-enroller ranking and completing 45% of the study enrollment. The company was the first to screen and randomize patients, and it managed to complete the trial execution twice as fast as the average. These achievements are a testament to Tilda's strategic site operating model and its commitment to leveraging advanced technologies for better clinical outcomes.

Tilda's Commitment to Diversity and Community

Tilda is dedicated to supporting Diversity, Equity, and Inclusion (DEI) goals through its site locations and community-centric recruitment strategies. By placing research sites in diverse communities, Tilda ensures broader participation and access to clinical trials. This approach not only helps in achieving more representative study results but also provides underrepresented populations access to new and advanced investigational treatment options. Participants often receive study-related medication at no cost and compensation for their time and travel, further enhancing community engagement and support.